| 产品名称 | 产品编号 | CAS编号 | 分子式 = 分子量 | 位单 | 联系QQ |
| 盐酸米托蒽醌; Mitoxantrone 2HCl | CFN60368 | 70476-82-3 | C22H29ClN4O6.2HCl = 517.4 | 20mg | QQ客服：2159513211 |
| Givinostat (ITF2357); Givinostat (ITF2357) | CFN60369 | 732302-99-7 | C24H27N3O4.HCl.H2O = 475.97 | 5mg | QQ客服：1413575084 |
| VX-702; VX-702 | CFN60370 | 745833-23-2 | C19H12F4N4O2 = 404.3 | 5mg | QQ客服：1413575084 |
| TAE226 (NVP-TAE226); TAE226 (NVP-TAE226) | CFN60371 | 761437-28-9 | C23H25ClN6O3 = 468.94 | 5mg | QQ客服：1457312923 |
| 阿贝司他; Abexinostat | CFN60372 | 783355-60-2 | C21H23N3O5 = 397.42 | 5mg | QQ客服：1457312923 |
| 马赛替尼; Masitinib (AB1010) | CFN60373 | 790299-79-5 | C28H30N6OS = 498.64 | 5mg | QQ客服：1413575084 |
| 达鲁舍替; Danusertib (PHA-739358) | CFN60374 | 827318-97-8 | C26H30N6O3 = 474.55 | 5mg | QQ客服：2159513211 |
| 卡格列净; Canagliflozin | CFN60375 | 842133-18-0 | C24H25FO5S = 444.52 | 5mg | QQ客服：2159513211 |
| 伊曲康唑; Itraconazole | CFN60376 | 84625-61-6 | C35H38Cl2N8O4 = 705.65 | 5mg | QQ客服：2159513211 |
| BIIB021; BIIB021 | CFN60377 | 848695-25-0 | C14H15ClN6O = 318.76 | 5mg | QQ客服：2159513211 |
| Degrasyn (WP1130); Degrasyn (WP1130) | CFN60378 | 856243-80-6 | C19H18BrN3O = 384.27 | 5mg | QQ客服：1413575084 |
| (-)-Blebbistatin; (-)-Blebbistatin | CFN60379 | 856925-71-8 | C18H16N2O2 = 292.33 | 5mg | QQ客服：2159513211 |
| AT7867; AT7867 | CFN60380 | 857531-00-1 | C20H20ClN3 = 337.85 | 5mg | QQ客服：1457312923 |
| GSK429286A; GSK429286A | CFN60381 | 864082-47-3 | C21H16F4N4O2 = 432.37 | 5mg | QQ客服：215959384 |
| FR 180204; FR 180204 | CFN60382 | 865362-74-9 | C18H13N7 = 327.34 | 5mg | QQ客服：1413575084 |
Cell. 2018 Jan 11;172(1-2):249-261.e12. doi: 10.1016/j.cell.2017.12.019.IF=36.216(2019)
Cell Metab. 2020 Mar 3;31(3):534-548.e5. doi: 10.1016/j.cmet.2020.01.002.IF=22.415(2019)
Mol Cell. 2017 Nov 16;68(4):673-685.e6. doi: 10.1016/j.molcel.2017.10.022.IF=14.548(2019)
ACS Nano. 2018 Apr 24;12(4): 3385-3396. doi: 10.1021/acsnano.7b08969.IF=13.903(2019)
Nature Plants. 2016 Dec 22;3: 16206. doi: 10.1038/nplants.2016.205.IF=13.297(2019)
Sci Adv. 2018 Oct 24;4(10): eaat6994. doi: 10.1126/sciadv.aat6994.IF=12.804(2019)